Results 91 to 100 of about 10,605 (184)
ABSTRACT Aim We estimated the coverage of children recorded in the Swedish National Airway Register (SNAR) and identified predictors of registration among those with asthma and moderate to severe asthma. Methods This study comprised 85 656 children aged 5–17 years with asthma, born 2000–2019 and living in Stockholm. The children were identified through
Hanna Karim +7 more
wiley +1 more source
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo +6 more
wiley +1 more source
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley +1 more source
Emerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications
PSTPIP2 acts as a key brake on myeloid inflammation by suppressing IL‐1β‐driven signalling, macrophage dysregulation and inflammation‐associated bone remodelling. Its emerging roles in CRMO/CMO, rheumatoid arthritis, SAPHO syndrome and bullous pemphigoid support its potential as a biomarker and therapeutic target.
Erdong Zhang +9 more
wiley +1 more source
Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran +2 more
wiley +1 more source
Management of chronic urticaria: Current status and future prospect
Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.
Andaç Salman +15 more
wiley +1 more source
ABSTRACT Background Allergic fungal rhinosinusitis (AFRS) is a persistent sinus condition caused by fungal allergies. Endoscopic sinus surgery (ESS) and postoperative systematic and local medical therapies are the most common treatment protocols. Although oral antifungals such as itraconazole are frequently utilised postoperatively, there is increasing
Khalaf Hamead +4 more
wiley +1 more source
Omalizumab in the management of patients with allergic (IgE-mediated) asthma
Thomas SandströmDepartment of Respiratory Medicine and Allergy, University Hospital, Umeå, SwedenAbstract: Immunoglobulin E (IgE) is central to the pathophysiology of allergic asthma.
Thomas Sandström
doaj
Cardiovascular Outcomes With Dupilumab Versus Omalizumab in Severe Asthma
Clinical &Experimental Allergy, EarlyView.
Po‐Cheng Shih +2 more
wiley +1 more source
The membrane‐active peptide Pep19‐2.5 reduces harmful inflammation by blocking activation of the NLRP3 inflammasome at trans‐Golgi network membranes. By targeting key membrane interactions, Pep19‐2.5 suppresses inflammatory IL‐1β production and alleviates allergic airway inflammation in mice, leading to reduced immune cell infiltration and improved ...
Jonas Engelhardt +16 more
wiley +1 more source

